ALNY Q4 2023 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$440M+31.2% YoY

Gross Profit

$354M80.5% margin

Operating Income

-$116M-26.5% margin

Net Income

-$138M-31.4% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

-41.4%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$45M

Stock-Based Comp.

$42M

Balance Sheet

Total Assets

$3.8B

Total Liabilities

$4.1B

Stockholders' Equity

-$221M

Cash & Equivalents

$813M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$440M	$335M	+31.2%
Gross Profit	$354M	$284M	+24.7%
Operating Income	-$116M	-$189M	+38.3%
Net Income	-$138M	-$207M	+33.6%

Revenue Segments

Product

$346M68%

GIVLAARI

$165M32%

Geographic Segments

UNITED STATES

$280M60%

Europe

$135M29%

Non-US Or Europe

$55M12%